BH-P-CEDER: A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 as a Single Agent and in Combination in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch Repair
OPEN TO ACCRUAL
I/II